SuperworthSonoma Pharmaceuticals profit margin SNOA
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- −10.3%
- Operating margin, 12 months
- −6.4%
- Net margin on a year earlier
- +13.5 pts
- Peer median
- 8.6%
Over the twelve months to Jun 30, 2026, Sonoma Pharmaceuticals kept −10.3% of its revenue as net profit, with an operating margin of −6.4% and a gross margin of 38.9%.
Five years earlier its net margin was −32.0%.
The median for 10 healthcare stocks of a similar size is 8.6%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2026 | −16.3% | −12.6% | 38.0% |
| FY2025 | −24.2% | −26.0% | 38.2% |
| FY2024 | −38.0% | −36.9% | 37.3% |
| FY2023 | −38.8% | −34.4% | 36.7% |
| FY2022 | −40.3% | −46.6% | 31.6% |
| FY2021 | −21.2% | −18.5% | 35.2% |
| FY2020 | −16.4% | −41.2% | 45.3% |
| FY2019 | −62.2% | −59.3% | 46.8% |
| FY2018 | −86.0% | −85.2% | 43.9% |
| FY2017 | 72.3% | n/a | 44.2% |
| FY2016 | −73.9% | −81.6% | 44.7% |
| FY2015 | −59.2% | −48.1% | 52.6% |
| FY2014 | 27.3% | −44.3% | 61.4% |
| FY2013 | −35.1% | −21.8% | 69.5% |
| FY2012 | −57.5% | −50.7% | 68.4% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q1 FY27 | −10.3% | +13.5 pts | −6.4% | |
| Q4 FY26 | −16.3% | +7.9 pts | −12.6% | |
| Q3 FY26 | −19.0% | +7.8 pts | −15.6% | |
| Q2 FY26 | −20.5% | +6.7 pts | −18.4% | |
| Q1 FY26 | −23.8% | +12.1 pts | −24.4% | |
| Q4 FY25 | −24.2% | +13.8 pts | −26.0% | |
| Q3 FY25 | −26.8% | +14.4 pts | −31.9% | |
| Q2 FY25 | −27.2% | +23.5 pts | −31.6% | |
| Q1 FY25 | −35.9% | +8.8 pts | −36.5% | |
| Q4 FY24 | −38.0% | +0.8 pts | −36.9% | |
| Q3 FY24 | −41.2% | +12.8 pts | −36.1% | |
| Q2 FY24 | −50.8% | −4.5 pts | −44.8% |
Against its peers
Companies in Healthcare nearest Sonoma Pharmaceuticals' size, closest first, today.
| Company | Profit margin |
|---|---|
| SNOASonoma Pharmaceuticals | −10.3% |
| OXBROXBRIDGE RE HOLDINGS | 4.7% |
| EDUCEducational Development | 8.6% |
| GTIMGood Times Restaurants | 1.7% |
| MDRRMedalist Diversified | 80.2% |
| BCGBinah Capital | 2.2% |
| VIPVulcan Infrastructure & Power | 1.0% |
| MXCMexco Energy | 23.3% |
| CKXCKX Lands | n/m |
| MSGMMotorsport Games | 16.2% |
| ATCHAtlasClear | 9.8% |
| Peer median | 8.6% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Sonoma Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.